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Potential antiproliferative effect of isoxazolo- and 
thiazolo coumarin derivatives on breast cancer mediated 
bone and lung metastases
The study highlights the current progress in the develop-
ment of coumarin scaffolds for drug discovery as novel 
anticancer agents in metastatic breast cancer. Eight com-
pounds, combining the coumarin core and five membered 
heterocycles (isoxazoles and thiazoles) in hydrazinyldiene- 
-chroman-2,4-diones, were characterized in terms of a po-
tential antiproliferative effect on bone (SCP1833) and lung 
(SCP4175) metastatic breast cancer cell lines using the 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide assay. Cell viability was evaluated after 48 and 72 h of 
treatment and the 50 % inhibitory concentrations were de-
termined. The results demonstrated dose- and time-depen-
dent activity, with the most potent molecules having a thia-
zole moiety, without or with additional methyl group(s) 
attached to the carbon(s) at position(s) 5 and/or 4 in the 
thiazole ring. These molecules possessed significantly 
higher potency against both test cell lines compared to 
4-hydroxycoumarin.
Keywords: chromandiones, breast cancer, metastatic cells, 
antiproliferative effect
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Anticancer drugs have traditionally been targeted to damage the aberrantly dividing 
cell by interrupting the cell division process. The reagents used for this purpose include 
DNA intercalating agents, topoisomerase inhibitors, cytoskeleton-disrupting agents and 
antimetabolites. Among these coumarin and coumarin-related compounds, members of 
the benzo-α-pyrone family, have been proven to exert antitumour eﬀ ects and cause sig-
niﬁ cant changes in the regulation of immune responses, cell growth and diﬀ erentiation 
(1). Antitumour activity is believed to be due to coumarin metabolites (e.g., 7-hydroxycou-
marin). Some coumarins display cytostatic properties while others have cytotoxic activi-
ties (2). Their inhibitory eﬀ ect on cell proliferation was conﬁ rmed in various carcinoma cell 
lines, including those of melanoma, leukaemia, renal carcinoma, prostate and breast can-
cer (1, 3–5). This activity was further validated by other investigators in human subjects as 
well (6, 7). A signalling pathway component was pointed out as a potential mechanism/
cellular target for antitumour activity of coumarins. 7-Hydroxycoumarin has been shown 
to inhibit tyrosine phosphorylation in EGF-stimulated tumour cells in a time- and dose-
dependent manner suggesting that this eﬀ ect may be achieved by reducing the tyrosine 
kinase activity of the EGF-receptor (8). In a separate study, in the absence of changes in the 
cyclin D1 level, mRNA/post-transcriptional eﬀ ect was observed pointing to the PI-3K/AKT 
pathway (9). Some coumarins and their active metabolite 7-hydroxycoumarin analogs 
have shown sulfatase and aromatase inhibitory activities, which is of particular interest in 
breast cancer chemotherapy. Coumarin based selective estrogen receptor modulators and 
coumarin-estrogen conjugates have also been described as potential anti-breast cancer 
agents (10).
Breast cancer is the most common malignancy among females and aﬀ ects approxi-
mately one in every ten women worldwide, being the second cancer type responsible for 
mortality in women a er lung cancer (11). It represents a group of highly heterogeneous 
lesions consisting of about 20 morphologically distinct subtypes with substantially diﬀ er-
ent molecular and/or biochemical signatures, clinical courses, and prognoses (12). A subset 
of normal or hyperplastic breast duct clusters showing malignancy-associated changes, 
including focal disruptions in the surrounding myoepithelial cell layer and basement 
membrane, expression of p53 and HER-2, and morphological signs of stromal and vascular 
invasion, can progress directly into invasive or metastatic lesions to other organs in the 
body, the favourite sites being the bones, lungs, liver or brain (12, 13).  Although an incur-
able condition, metastatic breast cancer treatment, chemotherapy drugs, antiestrogen and 
biologic therapy, can prolong life, delay the progression of cancer, relieve cancer-related 
symptoms and improve the quality of life (14–17). Despite an ever-expanding armamen-
tarium of cytotoxics, endocrine therapies, biologics and small-molecule inhibitors, meta-
static breast cancer is still the leading cause of death in women aged 40 to 55, which em-
phasizes the need for new drugs and combination therapies that will selectively act on 
speciﬁ c tumour targets and improve the overall survival with low toxicity.
In order to ﬁ nd new coumarin structure based drugs with anticancer activity, with 
special focus on (metastatic) breast cancer, we have synthesized compounds that combine 
the coumarin core and ﬁ ve membered heterocycles (isoxazoles and thiazoles) in hydra-
zinylidiene-chroman-2,4-diones (18). Based on the »hard and so  (Lewis) acids and bases« 
(HSAB) concept that electrophiles a ack the coumarine ring (19), the eight heterocyclic 
amines, isoxazoles and thiazoles, were derivatized to obtain diazonium ions which would 
be further used as electrophiles to a ack the coumarine ring at position 3. Isoxazole and 
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thiazole substituents were used based on the literature data pointing to the antiprolifera-
tive and tumour vascular-disrupting activity of their derivatives (20–23), with isoxazole 
and thiazole rings being important pharmacophores. Their anticancer eﬀ ects were dem-
onstrated in vivo (23) and in vitro (24–26) using various cancer cell lines, including breast 
cancer cells. Hence, a superior cellular eﬀ ect was expected in comparison with 4-hydroxy-
coumarin as a reference. Therefore, these isoxazolo- and thiazolo coumarin derivatives 
were further characterized for potential cytotoxic and apoptogenic eﬀ ects in the selected 
breast cancer cell lines, MCF-7 and MDA-MB-231. Three of the eight novel compounds 
were found to have cancer cell line dependent activity in MDA-MB-231, having IC50 values 
several-fold reduced compared to 4-hydroxycoumarin. Similar results were obtained 
when antiproliferative eﬀ ects on prostate cancer (LnCaP) and monocytic leukemia (U937) 
cell lines were evaluated. Reduced cell viability accompanied by increased apoptosis was 
shown by PARP cleavage and reduced activity of survival kinase Akt (18).
Considering the cell line dependent activity of the investigated 3-substituted thiazolo 
and isoxazolo hydrazinylidene-chroman-2,4-diones, the aim of this study was to test their 
antiproliferative eﬀ ects in SCP1833 and SCP4175 cell lines. These human MDA-MB-231 
derived breast cancer cell lines have diﬀ erent metastatic potentials in terms of their tissue 
tropisms and aggressiveness. Cell line 1833 is speciﬁ cally metastatic to the bone, while the 
highly aggressive cell line 4175 is speciﬁ c to the lung (27, 28). We found that three of the 
compounds reduced cell viability in a concentration-dependent manner and exhibited 
stronger antiproliferative activity than 4-hydroxycoumarin.
EXPERIMENTAL
Synthetic procedure and characterization of synthesized compounds
The synthetic procedure involved derivatization of the appropriate heterocyclic 
amines to obtain diazonium ions, which were further used as electrophiles to a ack the 
coumarine ring (29). This procedure has already been described in detail in a previous 
study (18). Brieﬂ y, cooled solutions (–10 °C) of the heterocyclic amines (10 mmol) in a mix-
ture of water (10 mL) and HCl (6 mol L–1, 40 mL) were slowly added to the aqueous solution 
of NaNO2 (0.14 g mL–1) and stirred vigorously. A erwards, a fresh solution of 4-hydroxy-
coumarin (4-HC, 10 mmol, 1.62 g) in 10 mL aqeous solution of NaOH (0.1 g mL–1) was 
added. The precipitates obtained were vacuum ﬁ ltered a er stirring for 15 min in an ice-
salt bath at –10 °C and 30 min at room temperature, washed three times with distilled 
water and dried in air. The recrystallization with ethanol as a solvent was used to purify 
the compounds. The reactions were monitored by TLC using diﬀ erent solvents.
Melting points of the compunds were determined on a Reichert heating plate 
(Reichert-Jung Optische Werke AG, Austria) and were uncorrected. Their structures were 
evaluated using spectroscopic techniques, including FTIR (Perkin-Elmer System 2000 
FTIR, USA), 1H NMR, 13C NMR and 2D NMR (Bruker-250 DRX Spectrometer, USA, using 
standard Bruker Topspin so ware) and MS (MS –Q-TOF premierspectrometer (ESI mode), 
Waters (USA). X-ray crystallography was done on Agilent SuperNova Dual, Cu at zero, 
Atlas diﬀ ractometer (Agilent Technologies, USA) (18, 30).
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Chemicals for cell culture studies
Synthesized compounds were dissolved in dimethyl sulfoxide (DMSO) to get 10 mmol 
L–1 stock solutions and stored at –20 °C. Further dilutions were made in complete Dul-
becco’s modiﬁ ed eagle’s medium (DMEM) containing 10 % fetal bovine serum (FBS). MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) was purchased from Sig-
ma (USA). FBS, DMEM, antibiotics and trypsin-ethylenediaminetetraacetic acid (EDTA) 
were obtained from Invitrogen, Switzerland, while 2-[4-(2-hydroxyethyl)piperazin-1-yl]
ethanesulfonic acid (HEPES) was from Roth (Germany).
Cell culturing
Human bone (SCP1833) and lung (SCP4175) metastatic cell lines were derived from 
the parental breast cancer cell line MDA-MB-231 and the procedure for their generation 
was described by Kang et al. (27) and Minn et al. (28). The SCP1833 and SCP4175 cells were 
cultured in Roswell Park Memorial Institute (RPMI) medium (Life Technologies Europe 
B.V., Switzerland) containing 4.5 g L–1 glucose, 10 % FBS, penicillin (100 units mL–1), strep-
tomycin (100 µg mL–1), 2 mmol L–1 N-acetyl-L-alanyl-L-glutamine and 10 mmol L–1 HEPES. 
All cell lines were incubated at 37 oC in an atmosphere containing 5 % CO2. Cells from 
exponentially growing cultures were used for experiments.
Cell viability assay
Antiproliferative eﬀ ects of the novel coumarin derivatives and 4-hydroxycoumarin 
(as a reference, purity ≥ 98.0%, Merck KGaA, Germany) on SCP1833 and SCP4175 cells were 
determined using the MTT assay. Brieﬂ y, 100 µL of the growth medium (DMEM) was 
poured into each well of a 96-well plate, plated with 5000 cells per well. Cells were allowed 
to a ach overnight and were then treated with the reference and synthesized compounds 
in increasing concentrations. A er 48 and 72 h incubation at 37 oC, 5 % CO2 and relative 
humidity 95 %, 20 µL of MTT reagent (5 mg mL–1) was added to each well and incubated 
further for 4 h at 37 oC. A erwards, 100 µL of the solvent consisting of 4 mmol L–1 HCl and 
0.1 % octylphenoxypolyethoxyethanol (Nonidet P-40, AppliChem, Germany) in isopropa-
nol was added to each well to solubilize the MTT crystals. The plates were covered with a 
foil and the cells were agitated on an orbital shaker for 15 min. Then, the absorbance was 
read at 590 nm in a microplate reader (SpectraMax M2 Fluorometer, BucherBiotec Inc., 
USA). All experiments were performed at least 3 times, with 4 wells for each concentration 
of the tested agent. Control cells were grown under the same conditions without addition 
of the test compounds.
Data presentation and statistical analysis
Cell survival was calculated relative to the untreated (vehicle-treated) controls. The 
50 % inhibitory concentration (IC50) was determined as the anticancer drug concentration 
causing 50 % reduction in cell viability and was calculated from the viability curves by 
linear interpolation between the values immediately above and below the 50 % inhibition 
using the Bliss so ware (Bliss Co, Castro Valley, CA 94552, USA).
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The results were presented as mean ± SD and statistical analysis was performed using 
the one-way analysis of variance (ANOVA), followed by Bonferroni’s post hoc test for mul-
tiple comparisons (GraphPad InStat version 3.00 for Windows NT, GraphPad So ware, San 
Diego, CA, USA).
RESULTS AND DISCUSSION
Structure and characteristics of the isoxazolo- and thiazolo derivatives of coumarin
Eight 3-substituted coumarin derivatives that combine the coumarin core and ﬁ ve 
membered heterocycles in hydrazinyldiene-chroman-2,4-diones (Table I, 1a–h) were pre-
viously synthesized by Jashari et al. (18). FTIR and NMR studies conﬁ rmed the presence of 
C=O at position 2 in the coumarin ring and substitution of the hydrogen at position 3 with 
isoaxozoles and thiazoles via a hydralazinylidene linker. The proposed structures were 
additionally conﬁ rmed by MS studies (Table I) (18). Based on the structure of 1f, for which 
mono-crystals were succesfully obtained, the hydralazinylidene structure of the synthe-
sized compounds was conﬁ rmed using X-ray crystallography (30).
Antiproliferation activity towards metastatic cells from breast cancer
Anticancer activities of the synthesized coumarin derivatives (1a–h) and 4-hydroxy-
coumarin (4-HC) as a reference were evaluated against SCP1833 and SCP4175 metastatic 
cancer cell lines from breast cancer a er 48 h (Figs. 1a and 2a) and 72 h (Figs. 2a and 2b) of 
Table I. Structure, yield and characteristics of the novel hydrazinylidiene-chroman-2,4-diones obtained a er 
the reaction of coumarin with the corresponding salts of the heterocyclic amines (18, 30)
Compound X Y R1 R2 R3
Yield
(%)
TOF-MS-ES+
(m/z)
M. p.
(oC)
1a N N H H H 93 280[M+Na]+ 225–227
1b O C CH3 H 92
272[M+H]+,
294[M+Na]+ 203–205
1c C S H H 82 274[M+H]
+,
296[M+Na]+ 209–211
1d C S H CH3 63
288[M+H]+,
310[M+Na]+ 218–220
1e C S CH3 CH3 65
302[M+H]+,
324[M+Na]+ 206–208
1f O C t-Bu H 86 314[M+H]
+,
336[M+Na]+ 225–227
1g C S H Br 69 353[M+H]
+,
375[M+Na]+ 217–219
1h O C H H 74 258[M+H]
+,
280[M+Na]+ 218–221
O
N
O
O
NH N
X
Y
R3
R2
R1
1
2
3
4
5
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the treatment. Both cancer cell lines were treated with increasing concentrations of the 
compounds from 1 to 500 µmol L–1 (1, 10, 20, 50, 100, 200 and 500 µmol L–1) and the 50 % 
inhibitory concentrations were then determined from the viability curves (Table II). One 
can see that cell viabilities were generally concentration- and time-dependent, which was 
conﬁ rmed by the sensitivity of the cancer cell lines, i.e., by the decrease of IC50 a er 72 h of 
treatment for almost all of the compounds. Namely, IC50 of almost all compounds, includ-
ing the reference 4-HC, dropped from 50–200 µmol L–1 in the 48th hour to 19–100 µmol L–1, 
a er 72 h (Table II). Exceptions were compound 1f (resembling structure 1b, i.e., oxygen at 
position 5 of the pentacycle and methyl replaced with t-butyl a ached to the carbon at 
Fig. 1. Viability of the human bone metastatic cell lines from breast cancer, SCP1833, a er: a) 48 h and 
b) 72 h of treatment with diﬀ erent concentrations of the novel chromandiones and the reference 
4-hydroxycoumarin, assessed by MTT assay. Mean (boxes) ± SEM (error bars), n = 4. * Statistically 
signiﬁ cant diﬀ erence from the control (p < 0.05) using Dunne ’s multiple comparison test.
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position 4) and 1c (having a thiazole moiety), which showed no time-dependent eﬀ ect on 
SCP4175. The potency of compound 1f for this cell line was lower than that of 4-HC (IC50 
200 µmol L–1 vs. 100 µmol L–1, respectively), while 1c showed IC50 of 50 µmol L–1, which was 
almost equal to the activity observed a er 48-h treatment against the same cell cancer line 
(Table II).
As reported in the previous study, in which breast cancer cell lines MCF-7 and MDA-
MB-231 were used (18), 4-HC did not show signiﬁ cant toxicity in this study either in any 
of the tested metastatic breast cancer cell lines and its IC50 was high, from 100–200 µmol 
L–1 a er 72- and 48-h treatment, respectively (Table II).
Fig. 2. Viability of the human lung metastatic cell lines from breast cancer, SCP4175, a er: a) 48 h and 
b) 72 h of treatment with diﬀ erent concentrations of the novel chromandiones and the reference 
4-hydroxycoumarin, assessed by the MTT assay. Mean (boxes) ± SEM (error bars), n = 4. * Statistically 
signiﬁ cant diﬀ erence from the control (p < 0.05) using Dunne ’s multiple comparison test.
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A er 48 h of treatment, a similar antiproliferative activity to that of 4-HC against 
SCP1833 and SPC4175 was observed for compounds 1a, 1b, 1f, 1h with a nitrogen or oxy-
gen at position 5 of the heterocycle, and 1g with a sulfur at position 3 of the heterocycle. 
Derivatives 1c, 1d and 1e, having a sulfur at position 3 of the ﬁ ve membered heterocycle, 
were more potent against viability of both cell lines a er 48 h compared to 4-HC. Within 
this period of treatment, no signiﬁ cant diﬀ erence between the eﬀ ects of these compounds 
on both cell lines (IC50 around 50 µmol L–1) was observed, except for the eﬀ ect of compound 
1c to which the SCP1833 cell line was less sensitive (IC50 99.90 ± 6.81 µmol L–1, Table II).
The SCP1833 cell line showed similar sensitivity to compounds 1a, 1f and 1h as to 
reference 4-HC a er 72 h of treatment, while sensitivity to other compounds was more 
pronounced, with compounds 1g and 1c being moderately potent (IC50 around 50 µmol L–1) 
and 1d and 1e being the most potent (IC50 around 20 µmol L–1) compared to 4-HC (IC50 
around 100 µmol L–1).
Similarly, the sensitivity of SPC4175 a er 72 h of treatment was similar to the reference 
for 1h and 1f (IC50 between 90 and 100 µmol L–1), while all other compounds had higher 
cytotoxic eﬀ ects than 4-HC, with the IC50 between 49.79 ± 6.29 (1b) and 19.78 ± 3.31 µmol 
L–1 (1e).
Speciﬁ cally, the inhibitory eﬀ ect of compound 1g, resembling the active sulfur con-
taining compounds 1c, 1d, and 1e, and having a bromine a ached to the carbon at position 
4, was time–dependent and this compound was less eﬀ ective than 1c, 1d and 1e a er 48 h 
of treatment. However, both cell lines responded more intensively a er 72 h with 1g than 
with 1d and 1e, but comparable to 1c.
Interestingly, compounds 1a and 1b having a nitrogen and an oxygen at position 5 of 
the heterocycle, respectively, showed almost two times higher potency against SCP4175 
(IC50 around 50 µmol L–1) than against SCP1833 (IC50 100.13 ± 4.94 µmol L–1 for 1a and 
81.39 ± 3.40 µmol L–1 for 1b) within 72 h of treatment, pointing to the cell type-dependent 
Table II. Cytotoxicity of 4-hydroxycoumarin and its novel derivatives against metastatic cancer cell lines from 
breast cancer as determined by the MTT assaya
Compound
IC50 (µmol L–1)
Cell line a er 48 h Cell line a er 72 h
SCP1833 SCP4175 SCP1833 SCP4175
4-HC > 200 > 200 100.23 ± 2.59 100.79 ± 6.17
1a > 200 > 200 100.13 ± 4.94   49.96 ± 4.29
1b > 200 > 200   81.39 ± 3.40   49.79 ± 6.29
1c 99.90 ± 6.81 50.23 ± 1.71   49.57 ± 0.59   49.88 ± 4.55
1d 50.14 ± 1.40 49.85 ± 3.95   19.78 ± 4.46   20.10 ± 1.26
1e 50.05 ± 1.12 50.22 ± 1.69   20.13 ± 1.35   19.78 ± 3.31
1f > 200 > 200 100.04 ± 4.58 200.23 ± 1.73
1g > 200 202.52 ± 7.410   50.05 ± 5.89   50.13 ± 5.64
1h > 200 > 200   95.74 ± 5.85   90.49 ± 2.23
a Mean ± SD from at least three independent experiments.
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sensitivity. For all other compounds, 1c, 1d, 1e and 1g, no signiﬁ cant diﬀ erence in the sen-
sitivity was observed between the two metastatic cell lines from breast cancer.
CONCLUSIONS
Eight compounds that combine the coumarin core and isoxazoles or thiazoles in hy-
drazinyldiene-chroman-2,4-diones were evaluated for their inhibitory activity against hu-
man lung and bone cancer cell lines derived from breast cancer. Of all the evaluated com-
pounds, compounds 1d and 1e, followed by 1c, showed stronger eﬀ ect on the viability of 
both cell lines during the whole study period than 4-hydroxycoumarin. The most potent 
molecules had a thiazole moiety a ached to the coumarin ring via hydrazinylidene linker 
at position 3, without or with additional methyl group(s) a ached to the carbon at position(s) 
5 and/or 4 in the thiazole ring. These results allow structural improvements in the 4-hy-
droxycoumarin nucleus and encourage eﬀ orts towards optimization of their chemo-ther-
apeutic proﬁ les.
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